BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 36480232)

  • 1. Clinical significance of preoperative neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in the prognosis of resected early-stage patients with non-small cell lung cancer: A meta-analysis.
    Cao W; Yu H; Zhu S; Lei X; Li T; Ren F; Zhou N; Tang Q; Zu L; Xu S
    Cancer Med; 2023 Mar; 12(6):7065-7076. PubMed ID: 36480232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.
    Leng J; Wu F; Zhang L
    Front Oncol; 2022; 12():734948. PubMed ID: 35651788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer.
    Huang Q; Diao P; Li CL; Peng Q; Xie T; Tan Y; Lang JY
    Medicine (Baltimore); 2020 Jan; 99(4):e18607. PubMed ID: 31977852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis.
    Platini H; Ferdinand E; Kohar K; Prayogo SA; Amirah S; Komariah M; Maulana S
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals.
    Guo W; Lu X; Liu Q; Zhang T; Li P; Qiao W; Deng M
    Cancer Med; 2019 Aug; 8(9):4135-4148. PubMed ID: 31197958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
    Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic value of preoperative lymphocyte-related systemic inflammatory biomarkers in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: a systematic review and meta-analysis.
    Shao Y; Li W; Wang D; Wu B
    World J Surg Oncol; 2020 Oct; 18(1):273. PubMed ID: 33097052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review.
    Zheng J; Cai J; Li H; Zeng K; He L; Fu H; Zhang J; Chen L; Yao J; Zhang Y; Yang Y
    Cell Physiol Biochem; 2017; 44(3):967-981. PubMed ID: 29179180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I-II gastric cancer.
    Sun X; Liu X; Liu J; Chen S; Xu D; Li W; Zhan Y; Li Y; Chen Y; Zhou Z
    Chin J Cancer; 2016 Jun; 35(1):57. PubMed ID: 27342313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients.
    Zhao QT; Yuan Z; Zhang H; Zhang XP; Wang HE; Wang ZK; Duan GC
    Int J Cancer; 2016 Jul; 139(1):164-70. PubMed ID: 26915723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are correlated with tumor-node-metastasis stages in patients with non-small cell lung cancer.
    Cheng H; Bhushan S; Li N; Xiao Z; Gao K
    J Cancer Res Ther; 2022; 18(6):1666-1673. PubMed ID: 36412428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor.
    Neofytou K; Smyth EC; Giakoustidis A; Khan AZ; Cunningham D; Mudan S
    Med Oncol; 2014 Oct; 31(10):239. PubMed ID: 25218270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
    Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
    Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
    Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
    Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic roles of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in gastrointestinal stromal tumours: a meta-analysis.
    Wei ZW; Huang WB; Yang DJ; Yuan YJ; He YL; Zhang CH
    Transl Cancer Res; 2020 Sep; 9(9):5128-5138. PubMed ID: 35117879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.